Daprodustat: a new approach to the treatment of anemia in chronic kidney disease

Czech version

Authors: Viktória Paulusová; Pavel Ryšánek; Martin Šíma; Ondřej Slanař
Authors‘ workplace: Farmakologický ústav, 1. lékařská fakulta, Univerzita Karlova a Všeobecná fakultní nemocnice v Praze
Published in: Čes. slov. Farm., 2024; 73, 110-112
doi: https://doi.org/10.36290/csf.2024.013

Overview

Daprodustat, also known under the trade name DUVROQ, is a small molecule developed by GlaxoSmithKline, which has become a promising drug in the field of anemia treatment in patients with chronic kidney disease. Daprodustat belongs to a group of drugs called hypoxia-inducible factor prolyl hydroxylase inhibitors. These drugs interfere with the regulation of erythropoietin, which is a key factor in the production of red blood cells. This drug was approved in Japan in June 2020 and clinical studies with it are ongoing in several countries around the world, where they focus on evaluating the effectiveness and safety in various populations of patients with chronic kidney disease.

Keywords:

daprodustat – hypoxia-inducible factor prolyl hydroxylase inhibitors – chronic kidney disease.

Sources

1. Dhillon S. Daprodustat: First Approval. Drugs. 2020;80(14):1491-7.

2. Kanai H, Nangaku M, Nagai R, Okuda N, Kurata K, Nagakubo T, et al. Efficacy and safety of daprodustat in Japanese peritoneal dialysis patients. Ther Apher Dial. 2021;25(6):979-87.

3. Beninger P. Daprodustat. Clin Ther. 2023;45(5):480-1.

4. Caltabiano S, Cizman B, Burns O, Mahar KM, Johnson BM, Ramanjineyulu B, et al. Effect of renal function and dialysis modality on daprodustat and predominant metabolite exposure. Clin Kidney J. 2019;12(5):693-701.

5. Baker DE. Daprodustat. Hospital Pharmacy. 2023;58(6):530-43.

6. Singh AK, Carroll K, McMurray JJV, Solomon S, Jha V, Johansen KL, et al. Daprodustat for the Treatment of Anemia in Patients Not Undergoing Dialysis. N Engl J Med. 2021;385(25):2313-24.

7. Sanghani NS, Haase VH. Hypoxia-Inducible Factor Activators in Renal Anemia: Current Clinical Experience. Adv Chronic Kidney Dis. 2019;26(4):253-66.

8. Ishii T, Tanaka T, Nangaku M. Profile of Daprodustat in the Treatment of Renal Anemia Due to Chronic Kidney Disease. Ther Clin Risk Manag. 2021;17:155-63.